Phase i study of 'dose-dense' pemetrexed plus @entity3003 /radiotherapy for locally advanced XXXX .

@entity1 @entity295 @entity137 @entity55 @entity5 @entity3003 @entity2910 @entity1149
BACKGROUND: This phase I study investigates the feasibility of @entity3003 plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic @entity1149 ( @entity1149 ). METHODS: Eligible @entity1 had Stage III or IV (oligometastatic) @entity1149 . @entity1 received XRT to 63 Gy in standard fractionation. @entity1 received concurrent @entity3003 (AUC = 6) during weeks 1 and 5 of XRT, and pemetrexed during weeks 1, 3, 5, and 7 of XRT. The starting dose level (level 1) of pemetrexed was 300 mg/m2. Following the finding of dose limiting @entity137 (DLT) in dose level 1, an amended dose level (level 1A) continued pemetrexed at 300 mg/m2, but with involved field radiation instead of extended nodal irradiation. Consolidation consisted of @entity3003 (AUC = 6) and pemetrexed (500 mg/m2) q3 weeks   2 -3 cycles. RESULTS: Eighteen @entity1 were enrolled. Fourteen @entity1 are evaluable for @entity137 analysis. Of the initial 6 @entity1 treated on dose level 1, two experienced DLTs (one grade 4 @entity295 , one prolonged grade 3 @entity2910 ). There was one DLT (grade 5 @entity55 ) in the 8 @entity1 treated on dose level 1A. In 16 @entity1 evaluable for response (4 with oligometastatic stage IV disease and 12 with @entity5 ), the median follow-up time is 17.8 months. Thirteen of 16 @entity1 had in field local regional response. The actuarial median survival time was 28.6 months in all @entity1 and 34.7 months (estimated) in stage III @entity1 . CONCLUSIONS: Concurrent @entity3003 with dose-dense (q2week) pemetrexed at 300 mg/m2 with involved field XRT is feasible and encouraging in @entity1 with locally advanced and oligometastatic @entity1149 .
